Skip to main content

Need urgent help? Start triage first, then route to emergency care.

Meds A-Z

Oclacitinib

Detailed information about Oclacitinib

Official label facts Owner quick guide first Marketing clearly labeled
Showing simplified owner view. Switch to Vet View for full technical detail.

Pet Owner Quick Guide

Start here: what this medicine is for, what it does, and when it's usually needed.

Usually used for:

Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

What it does:

Used for allergic and atopic dermatitis itch control in dogs.

When it's needed:

Not for use in dogs with serious infections; avoid use in very young dogs.

Call your vet sooner if you notice:

  • Not for use in dogs with serious infections; avoid use in very young dogs.

Commonly reported reactions:

  • (1 reports)
  • (1 reports)
  • (1 reports)

What to ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?
Talk to a Vet / Find a Vet Near You
Image coming soon
Oclacitinib

Oclacitinib

Drug type: Generic ingredient • Branded profile FDA branded products available

Species: Dog

Manufacturer: MSK

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Dog
Manufacturer: MSK
Form: Chewable Tablets, Tablet
Identifiers:
NADA: 141345 NADA: 141555 NDC Package: 54771-4322-1 NDC Package: 54771-4322-2 NDC Package: 54771-4322-3 NDC Package: 54771-4322-4 NDC Package: 54771-4323-1 NDC Package: 54771-4323-2 NDC Package: 54771-4323-3 NDC Package: 54771-4323-4 NDC Package: 54771-4324-1 NDC Package: 54771-4324-2 NDC Package: 54771-4324-3 NDC Package: 54771-4324-4 NDC Package: 54771-8721-1 NDC Package: 54771-8721-2 NDC Package: 54771-8721-3 NDC Package: 54771-8722-1 NDC Package: 54771-8722-2 NDC Package: 54771-8722-3
Source metadata:

Warnings / Contraindications

Not for use in dogs with serious infections; avoid use in very young dogs.

  • High: Not for use in dogs with serious infections; avoid use in very young dogs.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
31
Species represented
2
Most Reported Reactions
Reaction Cases Species Serious cases
1 Cat 1
1 Dog 1
1 Dog 1
1 Dog 1
1 Dog 1
1 Cat 1
1 Dog 1
1 Dog 1

Species coverage: Dog (28) Cat (4)

View detailed reaction table
Reaction Species Seriousness Frequency Reports
Dog Serious - 1
Cat Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Cat Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Cat Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Cat Serious - 1
Dog Non-serious - 1
Source metadata:

Storage & Handling

Store at room temperature.

Source metadata: No source yet.

Documents

Official label facts are separated from secondary summaries.

Promotional Materials (Marketing)

This content is marketing material and not clinical guidance.

No marketing assets are linked yet.

No source yet.

Source metadata: No source yet.
Talk to a Vet / Find a Vet Near You
Technical appendix (vet reference)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Medication catalog: Source PetWisePlus | Refreshed Feb 12, 2026, 7:40 PM UTC
  • Animal Drugs @ FDA: Source FDA | Refreshed Feb 16, 2026, 11:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Feb 16, 2026, 11:00 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Feb 16, 2026, 11:02 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Feb 9, 2026, 3:19 AM UTC
Official (FDA)
Identity: Generic ingredient • FDA branded products available
Official FDA brands: apoquel® apoquel® chewable
Case-reported brands (openFDA): MSK
Catalog species: Dog FDA-labeled species: Dog
Rx/OTC: RX
Form/route: Chewable Tablets, Tablet Oral
Applications: NADA 141-555 • NADA 141-345
Documents: 2 (FOI: 2) • SPL: 2 Label highlights Official documents
Safety (openFDA)
Top reactions: Dog 56 Cat 6 View
Case summaries: 7 (showing 7) View
openFDA reports are unverified and do not prove causation.

Explore
Linked using: Fda_Label (0.95), Fda_Label (0.95), Fda_Label (0.95)

Diagnosis Codes
ICD10_CM: L20.9
Atopic dermatitis, unspecified

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • Not for use in dogs with serious infections; avoid use in very young dogs. (Contraindication, High)
Top reaction signals
Application site discharge NOS (1) Application site hair loss (1) Asystole (1) Cardiorespiratory arrest (1) Cellulitis (1) Coma (1) Convulsion (1) Cyanotic mucous membranes (1) Deafness (1) Death (1) Dilated pupils (1) Drug administered at inappropriate site (1) Elevated serum alkaline phosphatase (ALP) (1) Elevated temperature (1) Fixed pupil (1) Increased heart rate (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
NADA: 141345 NADA: 141555 NDC Package: 54771-4322-1 NDC Package: 54771-4322-2 NDC Package: 54771-4322-3 NDC Package: 54771-4322-4 NDC Package: 54771-4323-1 NDC Package: 54771-4323-2 NDC Package: 54771-4323-3 NDC Package: 54771-4323-4 NDC Package: 54771-4324-1 NDC Package: 54771-4324-2 NDC Package: 54771-4324-3 NDC Package: 54771-4324-4 NDC Package: 54771-8721-1 NDC Package: 54771-8721-2 NDC Package: 54771-8721-3 NDC Package: 54771-8722-1 NDC Package: 54771-8722-2 NDC Package: 54771-8722-3 NDC Package: 54771-8723-1 NDC Package: 54771-8723-2 NDC Package: 54771-8723-3 NDC Package: 82712-2004-1
Package NDC Product NDC Form / Route Status
54771-4322-1 54771 -
54771-4322-2 54771 -
54771-4322-3 54771 -
54771-4322-4 54771 -
54771-4323-1 54771 -
54771-4323-2 54771 -
54771-4323-3 54771 -
54771-4323-4 54771 -
54771-4324-1 54771 -
54771-4324-2 54771 -
54771-4324-3 54771 -
54771-4324-4 54771 -
54771-8721-1 54771 -
54771-8721-2 54771 -
54771-8721-3 54771 -
54771-8722-1 54771 -
54771-8722-2 54771 -
54771-8722-3 54771 -
54771-8723-1 54771 -
54771-8723-2 54771 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

  • N-141555-Q-0004-OT-AA_foi.pdf • FOI summary • Official • Oct. 17, 2024
    FDA FOI summary for application 141555
  • UCM363901.pdf • FOI summary • Official • Aug. 17, 2023
    FDA FOI summary for application 141345

Data Sources & Revision History

Every non-trivial field is expected to include provenance and update timestamps.

Official 5 Clinical 1 Manufacturer 0 Marketing 0
Current Field Facts
  • storage_handling: Store at room temperature. (Clinical, 2026-02-12)
  • contraindications: Not for use in dogs with serious infections; avoid use in very young dogs. (Official, 2026-02-12)
  • side_effects: GI upset, lethargy; immune modulation may increase infection risk. (Official, 2026-02-12)
  • usage: Used for allergic and atopic dermatitis itch control in dogs. (Official, 2026-02-12)
Recent Revisions
  • side_effects updated 2026-02-12 19:40 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-02-12 19:40 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-02-12 19:40 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
apoquel® chewable
RX
Oclacitinib
Chewable Tablets Oral
Zoetis Inc. NADA 141-555 Approved Oct 17, 2024
apoquel®
RX
Oclacitinib
Tablet Oral
Zoetis Inc. NADA 141-345 Approved Aug 17, 2023

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
3.6, 5.4, or 16 mg of oclacitinib as oclacitinib maleate per tablet
Dogs
Indication

Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

Dosage

The dose is 0.18 to 0.27 mg oclacitinib/lb (0.4 to 0.6 mg oclacitinib/kg) body weight, administered orally, twice daily for up to 14 days, and then administered once daily for maintenance therapy.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
3.6, 5.4, or 16 mg of oclacitinib as oclacitinib maleate per tablet
Dogs
Indication
Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.
Dosage
Administer orally 0.18 to 0.27 mg/per pound of body weight (0.4 to 0.6 mg/kg body weight) twice daily for up to 14 days; then administered once daily for maintenance therapy.
Limitations
APOQUEL is not for use in breeding dogs, or pregnant or lactating bitches. The use of APOQUEL has not been evaluated in combination with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents. Dogs receiving APOQUEL should be monitored for the development of infections, including demodicosis, and neoplasia.

FDA page: Open in Animal Drugs @ FDA

Official Documents (FDA)

Direct links to FDA-hosted PDFs and SPL packages (when available).

Documents
  • Summary

    Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary
    Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Usage

Used for allergic and atopic dermatitis itch control in dogs.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Not for use in dogs with serious infections; avoid use in very young dogs.

Side Effects

GI upset, lethargy; immune modulation may increase infection risk.

Source: FDA openFDA • Reference

Top Reported Reactions (openFDA)

Aggregated reaction terms from FDA openFDA reports (not verified; does not prove causation).

Dog
Digestive
Vomiting (99) Diarrhea (71) Decreased appetite (31)
Neurologic
Tiredness (lethargy) (52) Tiredness (lethargy) (35)
Behavior
Behavioral disorder (unspecified) (30) Behavioral disorder (unspecified) (1) Behavioral disorder (unspecified) (1) Behavioral disorder (unspecified) (1) Behavioral disorder (unspecified) (1) Behavioral disorder (unspecified) (1) Behavioral disorder (unspecified) (1)
Effectiveness
Lack of efficacy - NOS (79)
Other
Not eating (41) Deafness (3) Deafness (3) Deafness (3) Deafness (2) Deafness (2) Deafness (2) Panting (2) Panting (2) Panting (2) Panting (2) Panting (2) Panting (2) Administration error NOS (1) Administration error NOS (1) Administration error NOS (1) Application site discharge NOS (1) Application site discharge NOS (1) Application site discharge NOS (1) Application site discharge NOS (1) Application site discharge NOS (1) Application site discharge NOS (1) Asystole (1) Asystole (1) Asystole (1) Asystole (1) Asystole (1) Asystole (1) Cardiorespiratory arrest (1) Cardiorespiratory arrest (1) Cardiorespiratory arrest (1) Cardiorespiratory arrest (1) Cardiorespiratory arrest (1) Cardiorespiratory arrest (1) Cellulitis (1) Cellulitis (1) Cellulitis (1) Cellulitis (1) Cellulitis (1) Cellulitis (1) Coma (1) Coma (1) Coma (1)
Cat
Digestive
Vomiting (1)
Skin & allergy
Application site hair loss (1)
Other
Drug administered at inappropriate site (1) Pacing (1) Shivering (1) Uncomfortable (1)

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Boxer (German Boxer), Female, 2.3 year, 28.7 kilogram • Drug: MSK, Tablet, Oral, Dose: 16 Milligram per dose, Frequency: 1 per day • Reactions: Death, Injection site discharge NOS, Swollen limb, Pain NOS, Not eating… • Outcome: Died

  • Report ID: USA-USFDACVM-2025-US-055852
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 2.30 Year
  • Weight: 28.700 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet
  • Dose: 16 Milligram per dose
  • Frequency: 1 per day
Reactions Reported:
Death Injection site discharge NOS Swollen limb Pain NOS Not eating Not drinking Uncomfortable Elevated temperature Increased heart rate Increased respiratory rate Pitting oedema Injection site skin discolouration Injection site serosanguinous discharge Injection site reaction NOS Wound Cellulitis Local skin slough Convulsion Cardiorespiratory arrest Panting Fixed pupil Dilated pupils Cyanotic mucous membranes Coma Neurological signs NOS Premature ventricular contractions Ventricular fibrillation Asystole
Outcomes: Died

Dog, Mixed (Dog), Male, 10 year, 39 kilogram • Drug: MSK, Oral • Reactions: Elevated serum alkaline phosphatase, Panting, Underdose • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-056107
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 10.00 Year
  • Weight: 39.000 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
Reactions Reported:
Elevated serum alkaline phosphatase Panting Underdose
Outcomes: Outcome Unknown

Dog, Terrier - Fox Wire, Male, 10.8 year, 9.68 kilogram • Drug: MSK, Oral, Dose: 5.40 Milligram per unknown, Frequency: 24 per hour • Reactions: Deafness, Tympanic rupture, Application site discharge NOS • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-053873
  • Serious AE: Yes
  • Treated For AE: No
  • Sex: Male
  • Age: 10.80 Year
  • Weight: 9.680 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Dose: 5.40 Milligram per unknown
  • Frequency: 24 per hour
Reactions Reported:
Deafness Tympanic rupture Application site discharge NOS
Outcomes: Outcome Unknown

Dog, Dog (unknown), Unknown • Drug: MSK, Tablet, chewable, Oral, Dose: 16 Milligram per animal • Reactions: Systemic disorder NOS, Suspect counterfeit product • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2025-US-066567
  • Serious AE: No
  • Treated For AE: No
  • Sex: Unknown
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet, chewable
  • Dose: 16 Milligram per animal
Reactions Reported:
Systemic disorder NOS Suspect counterfeit product
Outcomes: Recovered/Normal

Dog, American Pit Bull Terrier, Male, 12 year, 30 kilogram • Drug: MSK, Tablet, Oral • Reactions: Deafness • Outcome: Recovered with Sequela

  • Report ID: USA-USFDACVM-2025-US-048607
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 12.00 Year
  • Weight: 30.000 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet
Reactions Reported:
Deafness
Outcomes: Recovered with Sequela

Cat, Male, 12 year, 8.618 kilogram • Drug: MSK, Tablet, Unknown, Dose: 4 Milligram per dose • Reactions: Shivering, Pacing, Uncomfortable, Vomiting • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2023-US-005653
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 12.00 Year
  • Weight: 8.618 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Tablet
  • Dose: 4 Milligram per dose
Reactions Reported:
Shivering Pacing Uncomfortable Vomiting
Outcomes: Recovered/Normal

Cat, Domestic Shorthair, Female, 11 year, 4.536 kilogram • Drug: MSK, Oral • Reactions: Application site hair loss, Drug administered at inappropriate site • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2019-US-018159
  • Serious AE: Yes
  • Treated For AE: No
  • Sex: Female
  • Age: 11.00 Year
  • Weight: 4.536 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
Reactions Reported:
Application site hair loss Drug administered at inappropriate site
Outcomes: Ongoing

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

Store at room temperature.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.